Innate Immune Modulators

For The Prevention of Complications Associated with Respiratory Viral Infections

Ena Respiratory

About Us

ENA Respiratory is a clinical-stage pharmaceutical company developing innate immune modulators administered as convenient, self-administrated nasal products for the prevention of complications resulting from respiratory viral infections in populations at risk due to:

  • age (60 years old and over);
  • underlying medical conditions, or
  • occupational risk

The ENA team has a long history of successful drug development in respiratory diseases and seeks to leverage this expertise to meet the considerable unmet need that still exists for these vulnerable populations.

At-Risk Populations Due to Comorbid Conditions

  • COPD, Asthma
  • Congestive Heart Failure
  • Chronic Kidney Disease
  • Diabetes
  • Lymphoma/Chronic Leukemia
  • High-Dose Corticosteroids

At Risk Occupations

  • Healthcare workers
  • Teachers
  • Transportation workers
  • Military Personnel

 

 

Our most advanced drug, INNA-051 is in clinical development. Add a link to the INNA-051 product page.

Our Investors

Headquartered in Melbourne Australia, the company has secured a Series A investment.

Brandon Capital

Brandon Capital

Find out more
Minderoo Foundation

Minderoo Foundation

Find out more

 Our Partnerships

BLUE KNIGHT

BLUE KNIGHT

In 2022, ENA Respiratory was selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation and U.S. BARDA.

Find out more
COPD FOUNDATION

COPD FOUNDATION

In 2022, ENA Respiratory partnered with the US-based COPD Foundation to accelerate the clinical development of INNA-051 in COPD through its access to patients, a global network of accredited centres, scientific expertise, and patient investigators.

Find out more
U.S. Department of Defense

U.S. Department of Defense

In 2023, ENA Respiratory was awarded a USD8.18 million contract from the U.S. Department of Defense to support the ongoing development of INNA-051.

Find out more